AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Jaguar Health's 15-min chart shows Bollinger Bands Narrowing, KDJ Death Cross.
ByAinvest
Friday, May 9, 2025 12:46 pm ET1min read
Jaguar Health's 15-minute chart has recently exhibited Bollinger Bands Narrowing, a signal indicating decreasing stock price fluctuations, coupled with a KDJ Death Cross at 05/09/2025 12:30. This suggests that the momentum of the stock price is shifting towards the downside and may continue to decrease in magnitude.
Jaguar Health Inc (JAGX) is set to release its quarterly earnings on May 12, 2025, with analysts expecting a notable increase in revenue. According to one analyst estimate, the company is projected to report a 20.0% rise in revenue to $2.821 million, up from $2.35 million a year ago [1]. However, the earnings preview also indicates a potential loss of $18.00 per share, based on the mean analyst estimate from LSEG data.The San Francisco-based company has received a "strong buy" rating from Wall Street, with a median 12-month price target of $16.00, above its last closing price of $8.70. The mean earnings estimate has remained unchanged over the past three months.
In addition to the financial outlook, technical analysis of Jaguar Health's stock has shown recent narrowing of Bollinger Bands, suggesting decreasing stock price fluctuations. This was coupled with a KDJ Death Cross on May 9, 2025, at 12:30, signaling a potential shift in momentum towards the downside. This could indicate a continued decline in stock price volatility and a potential decrease in stock price magnitude.
Investors should closely monitor Jaguar Health's earnings report and the ongoing technical indicators to assess the potential impact on the company's stock price.
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3RH2B6:0-jaguar-health-inc-expected-to-post-a-loss-of-18-00-a-share-earnings-preview/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet